Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.15B 11.48B 10.4B 19.51B 1,344B 19.66B 137B 52.73B 682B 52.66B 51.5B 2,174B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.29B 10.67B 9.67B 18.14B 1,250B 18.28B 127B 49.03B 634B 48.97B 47.88B 2,022B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 33.15
Extreme 33.15
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap. Importance
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

55,511 0.0522%
02/04/25 Issuer sale

Chief Technology Officer

265,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+133.85% 14.02B
-2.47%-6.48%+38.23%-7.00% 79.26B
-1.99%-1.22%+511.53%+27.44% 58.56B
+1.57%+0.62%-16.15%-34.72% 58.62B
-0.56%-3.68%-11.53%+25.63% 48.75B
-0.29%-0.19%+1.21%+154.61% 46.32B
-0.55%-2.11%+49.23%-15.66% 32.12B
-0.37%-3.95%+46.50%+91.78% 24.77B
-1.91%-6.22%-2.91%+151.66% 21.5B
-1.92%-2.31%+62.94%+96.25% 15.97B
Average -0.85%-1.69%+67.90%+62.38% 39.99B
Weighted average by Cap. -0.90%-1.76%+88.05%+39.69%

Financials

2023 2024
Net sales 464M 402M 380M 345M 646M 44.51B 651M 4.53B 1.75B 22.58B 1.74B 1.71B 72.01B 681M 590M 557M 505M 948M 65.26B 955M 6.65B 2.56B 33.11B 2.56B 2.5B 106B
Net income -140M -121M -114M -104M -194M -13.39B -196M -1.36B -525M -6.79B -525M -513M -21.66B -74.68M -64.69M -61.12M -55.41M -104M -7.16B -105M -729M -281M -3.63B -280M -274M -11.58B
Net Debt -481M -417M -394M -357M -669M -46.1B -674M -4.7B -1.81B -23.39B -1.81B -1.77B -74.59B -984M -853M -806M -730M -1.37B -94.32B -1.38B -9.61B -3.7B -47.86B -3.7B -3.61B -153B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!